Vial A: Simultest Leucogate CD45/CD14, FITC-labeled CD45~0.025 mg/mL. PE-labeled CD14~0.013 mg/mL,Vial B: Simultest IgG1/IgG2a Isotype Control, FITC-labeled IgG1~0.013 mg/mL PE-labeled IgG2a~0.013 mg/mL,Vial C: Simultest CD3/CD19, FITC-labeled CD3~0.025 mg/mL, PE-labeled CD19~0.003 mg/mLVial D: Simultest CD4/CD8, FITC-labeled CD4~0.002 mg/mL, PE-labeled CD8~0.006 mg/mLVial E: Simultest CD3/Anti-HLA-DR, FITC-labeled CD3~0.025 mg/mL, PE-labeled Anti-HLA-DR~0.003 mg/mLVial F: Simultest CD3/CD16+CD56, FITC-labeled CD3~0.025 mg/mL, PE-labeled CD16~0.006 mg/mL, PE-labeled CD56~0.013 mg/mLVial G: 10X FACS Lysing Solution, Contains<15% formaldehyde, <50% diethylene glycol, sodium citrate, and heparin.
共有 1 個藥物證書使用此成份
- 申請商
- 新加坡商必帝股份有限公司台灣分公司
- 適應症
- 含量
- 發證日期
- 2005-08-12